CDH1 and pancreatic neoplasm: Fifty (45%) pancreatic cancer specimens were assigned to the low RAB5 expression group and 61 (55%) were assigned to the high RAB5 expression group; 63 (57%) pancreatic cancer specimens were assigned to the high E-cadherin expression group and 48 (43%) were assigned to the low E-cadherin expression group (Figure 1A).